HCM KYG4672N1198

Bericht

Verzögert London Stock Exchange - 17:35 15.08.2022
229.00	GBX		+1.78%

09.08.	HUTCHMED (CHINA) LIMITED : Goldman Sachs klebt neutral	MM
09.08.	Inmagene Biopharmaceuticals und HUTCHMED (China) Limited geben den ersten Teilnehmer an der globalen Phase I-Studie von IMG-004 bekannt	CI
08.08.	SEKTOR-UPDATE : Aktien des Gesundheitswesens steigen am frühen Montag an	MT

News

Analystenempfehlungen

Andere Sprachen

Pressemitteilungen

Offizielle Publikationen

Branchen-News

Nachrichten in anderen Sprachen über HUTCHMED (CHINA) LIMITED

09.08.	HUTCHMED CHINA : Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial ..
09.08.	Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004
09.08.	Inmagene Biopharmaceuticals and HUTCHMED Limited Announce First Participant in Global P..
08.08.	SECTOR UPDATE : Health Care Stocks Edge Higher Early Monday
08.08.	Tagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patie..
08.08.	Hutchmed Says Global Phase 3 Study of Colorectal Cancer Drug Meets Primary Endpoint
08.08.	HUTCHMED CHINA : Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its P..
08.08.	AstraZeneca Says Lung Cancer Combination Therapy Showed 49% Objective Response Rate
08.08.	AstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Tri..
08.08.	HUTCHMED Says Late-Stage Trial of Metastatic Colorectal Cancer Drug Meets Endpoints
08.08.	Hutchmed's Colorectal Cancer Drug Improves Survival in Late-stage Study
08.08.	HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primar..
08.08.	HUTCHMED Limited Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met It..
08.08.	HUTCHMED Limited Announces Fruquintinib Global Phase III FRESCO-2 Study in Metastatic C..
01.08.	HUTCHMED CHINA : Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refr..
01.08.	SECTOR UPDATE : Health Care Stocks Lean Lower Premarket Monday
01.08.	Hutchmed (China) Loss in H1 as Expenses Rise; Revenue Grows
01.08.	TRANSCRIPT : HUTCHMED Limited, H1 2022 Earnings Call, Aug 01, 2022
01.08.	Hutchmed H1 Net Loss Widens, Revenue Rises
01.08.	HUTCHMED CHINA : Reports 2022 Interim Results and Provides Business Updates - Form 6-K
01.08.	HUTCHMED Limited Reports Earnings Results for the Half Year Ended June 30, 2022
01.08.	HUTCHMED Reports 2022 Interim Results and Provides Business Updates
01.08.	HUTCHMED (China) Initiates Bridging Study of Tazemetostat in Relapsed or Refractory Fol..
01.08.	Hutchmed Launches Bridging Study of Lymphoma Drug in China
01.08.	Hutchmed Starts Bridging Study Follicular Lymphoma Treatment in China
01.08.	HUTCHMED Initiates a Bridging Study of Tazemetostat in Patients with Relapsed/Refractor..
01.08.	HUTCHMED Limited Initiates A Bridging Study of Tazemetostat in Patients with Relapsed/R..
28.07.	SEC Chair Stresses Need to Reach Audit Deal With Chinese Regulators
26.07.	China’s Securities Watchdog Denies Plan to Help Firms Avoid US Delisting
20.07.	Deal to Avoid Delisting of 200 Firms in US Bourses Remains Unclear
15.07.	HUTCHMED CHINA : Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Pati..
15.07.	Hutchmed Begins Phase 1 Trial of Investigational Drug in Patients With Advanced Tumors
15.07.	HUTCHMED Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients ..
15.07.	HUTCHMED Limited Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in P..
13.07.	HUTCHMED CHINA : Highlights First Presentation of Results of the SAVANNAH Global Phase II ..
13.07.	Hutchmed Says Phase 2 Study to Treat Patients With MET-Driven Non-Small Lung Cancer Sho..
13.07.	HUTCHMED Highlights First Presentation of Results of the SAVANNAH Global Phase II Trial..
13.07.	HUTCHMED Limited Highlights First Presentation of Results of the SAVANNAH Global Phase ..
06.07.	Hutchmed, Inmagene Dose First Patient in Global Clinical Study of Dermatitis Drug
06.07.	HUTCHMED CHINA : Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial..
06.07.	Hutchmed, Inmagene Dose First Participant in Early-Stage Trial of Eczema Drug; Shares D..
06.07.	Hutchmed, Inmagene Biopharmaceuticals Dose First Participant in Phase 1 Eczema Trial
06.07.	Inmagene Biopharmaceuticals and HUTCHMED Announce First Participants in Global Phase I ..
30.06.	Certain American Depositary Shares of HUTCHMED Limited are subject to a Lock-Up Agreeme..
30.06.	Certain Ordinary Shares of HUTCHMED Limited are subject to a Lock-Up Agreement Ending o..
29.06.	HUTCHMED CHINA : Blocklisting Six Monthly Return - Form 6-K
27.06.	HUTCHMED CHINA : to Announce 2022 Half-Year Financial Results - Form 6-K
27.06.	HUTCHMED to Announce 2022 Half-Year Financial Results
01.06.	HUTCHMED CHINA : Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China - F..
01.06.	HUTCHMED Secures Regulatory Clearance for Use of Oncology Drug Tazverik in China's Hain..
01.06.	HUTCHMED Announces TAZVERIK(R) Approved to be Used in Hainan Pilot Zone in China
24.05.	HUTCHMED CHINA : - Form 6-K
17.05.	Asian ADRs Move Up in Tuesday Trading
16.05.	Appointment of Non–Executive Director
16.05.	HUTCHMED Limited Announces Board Changes
02.05.	SECTOR UPDATE : Health Care Stocks Largely Sit Out Afternoon Recovery
02.05.	Top Midday Decliners
02.05.	SECTOR UPDATE : Health Care Stocks Sinking with Broader Monday Markets
02.05.	SECTOR UPDATE : Health Care
02.05.	SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Monday
02.05.	SECTOR UPDATE : Health Care
02.05.	Hutchmed Says FDA Requires Additional Trial for Approval of Advanced Tumor Drug; Shares..
02.05.	US FDA Says Hutchmed (China)'s Application For Pancreatic Tumor Treatment Does Not Supp..
02.05.	HUTCHMED ADSs Slide After FDA Rejects Surufatinib
02.05.	TRANSCRIPT : HUTCHMED Limited - Special Call
02.05.	HUTCHMED CHINA : INSIDE INFORMATION - Form 6-K
02.05.	HUTCHMED : FDA Rejects Surufatinib Application in Neuroendocrine Tumors
02.05.	HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Tr..
27.04.	HUTCHMED CHINA : Annual General Meeting held on April 27, 2022 – Poll Results - Form..
21.04.	HUTCHMED CHINA : Vesting of awards under the Long Term Incentive Plan - Form 6-K
05.04.	China’s Securities Watchdog Eases Rules on Financial Inspections of Offshore List..
31.03.	HUTCHMED CHINA : Update on Status under Holding Foreign Companies Accountable Act - Form 6..
31.03.	Hutchmed (China) Says Inclusion in US Audit Law Will Not Impact Operations But Flags 20..
31.03.	Update on Status under Holding Foreign Companies Accountable Act
23.03.	HUTCHMED CHINA : Annual Report and Notice of Annual General Meeting - Form 6-K

1 2 3 4 5 6 7 8 Weiter

Anstehende Termine für HUTCHMED (CHINA) LIMITED

07.09.22

Jefferies Asia Forum

Finanzkalender des Unternehmens

Anstehende Branchentermine

18.10.22	JOHNSON & JOHNSON : Q3 2022 Ergebnisveröffentlichung
01.11.22	PFIZER INC. : Q3 2022 Ergebnisveröffentlichung (geplant)
01.11.22	ELI LILLY AND COMPANY : Q3 2022 Ergebnisveröffentlichung
04.11.22	ABBVIE INC. : Q3 2022 Ergebnisveröffentlichung (geplant)

Mehr Termine

Branche

Gesundheitspflege
	Pharmazie und Biotechnologie
		Pharmazie und Biotechnologie
			Pharmazeutika
				Pharmazeutika - Andere